brain lesions

New fears and anxiety associated with MS progression

Note: This column refers to the authorā€™s own experience with Gilenya (fingolimod). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. On a recent Friday, all was calm and peaceful in my household. I was bundled up in my bed watching…

Smoking Linked to Worse Outcomes in RRMS Patients After 10 Years

Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years,Ā according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…

Estriol Plus Copaxone May Protect Against Nerve Damage in RRMS

Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) ā€” a marker of nerve damage ā€” in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…

Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…

Expert Voices: Exploring the connection between vitamin D and MS

In this installment of our ā€œExpert Voicesā€ series, Multiple Sclerosis News Today asked Kassandra Munger to answer some of your questions about the connection between vitamin D levels and multiple sclerosis (MS). Munger received her bachelor’s in biology from the University of Rochester in 1997, master’s in…

Study Probes Why Some Don’t Experience Placebo Effect

Differences in the physical architecture of the brain may explain why some people with multiple sclerosis (MS), but not others, experience a placebo effect, according to a new study. The results suggest that MS itself may make some individuals unable to experience the benefits of a placebo. “Our findings…

Cerebellar Lesions in RRMS Linked to Worsening Manual Dexterity

The number of lesions affecting the cerebellum ā€” a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture ā€” predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, ā€œCerebellar pathology and…

#MSVirtual2020 ā€“ Zeposia Still Prevents Relapses in Relapsing MS Patients After 3 Years, Trial Data Show

Zeposia (ozanimod) oral capsules continue to safely and effectively prevent relapses and disability progression in people with relapsing forms of multiple sclerosis (MS), according to three-year data from a Phase 3 extension clinical trial. ā€œGaining insight into long-term therapeutic outcomes can enable clinicians to identify the most appropriate…